Iktos news
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design.
Under the 3-year agreement, Sygnature will deploy Iktos’ de novo generative design software Makya™, which
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design today announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain.
Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies and software Makya™, it
- Topic: Makya: AI-driven de novo drug design and multi-parametric optimisation
- Recording Duration: 56:50
- Webinar Start Time: Dec 7, 2021, 10 - 11 AM CET & 5 - 6 PM CET
Webinar on Spaya: AI-Enhanced Retrosynthesis for Chemists ...